CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 42 enrolled
Drug / intervention
Daratumumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03236428
NCT03236428Phase 2Active
CompareCT.gov

A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute·interventional·Posted Aug 1, 2017·Updated Mar 27, 2026

In Brief

A Phase 2 clinical trial evaluating Daratumumab for Monoclonal Gammopathy and Smoldering Multiple Myeloma. Active but no longer recruiting, targeting 42 participants across 6 sites.

Detailed Summary

This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMonoclonal Gammopathy, Smoldering Multiple Myeloma
CountriesUnited States
CollaboratorsJanssen Pharmaceuticals, Multiple Myeloma Research Consortium, Blood Cancer Research Partnership, The Leukemia and Lymphoma Society

Timeline

Phase 2Active
2018201920202021202220232024202520262027
First PostedAug 1, 2017
Enrollment StartNov 24, 2017
Primary CompletionOct 4, 2021
Study CompletionOct 4, 2026
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 8.9 years ago

Interventions

Daratumumabdrug

Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule